Abstract-Human G-CSF, a single chain polypeptide containing 174 amino acid residues (MW=18,800, pI=6.1), is one of the hemopoietic growth factors. Development of inexpensive and simple culture media is always favorable for commercial production of recombinant proteins in E. coli.
I. INTRODUCTION
Development of inexpensive and simple culture media is always favorable for commercial production of recombinant proteins in E. coli. Many of the efforts aimed at increasing recombinant protein production in bacterial strains have been directed to maximizing the biomass production with the high cell density cultivation method and little is known about the effects of media composition on the expression of recombinant proteins [1, 2] .
Hence In this study, at first the effects of medium composition on the production of recombinant human Granulocyte-Colony Stimulating Factor (rh-GCSF) was investigated in batch culture; and then a simple and cost-effective downstream process for the economical production of rh-GCSF is developed.
The high-level expression of eukaryotic proteins in E. coli often leads to formation of insoluble inclusion bodies (IBs) in the cytoplasm or periplasm. Inclusion bodies are dense but porous particles of aggregated protein that Usually only one or a few different proteins are inside the IB, and no ribosomal components or nucleic acids are resent and they are held together by non-covalent hydrophobic or ionic bonds.
IBs have some native-like protein structures, but also have an increased amount of non-native β-sheet [3] . Three Factors that contribute to inclusion body (IB) formation: 1) Inclusion bodies form most often as a result of overexpression of a non-native protein. 2) Hydrophobic proteins form IBs more readily. 3) Non-native proteins with disulfide bonds are prone to form IBs because the disulfide bridge cannot form in the cytosol Accidental oxidation can also lead to improper disulfide formation [ 3, 5] . Culture conditions such as temperature, pH, and nutrient supply play a very important role in controlling the partition of the recombinant protein into soluble and insoluble fractions. Recovery of active material from (IBs) is often difficult and involves two general steps: protein solubilization in a denaturant and protein refolding [3] amino acid residues (MW=18,800, pI=6.1), is one of the hemopoietic growth factors which plays an important role in stimulating proliferation, differentiation, and functional activation of blood cells. It contains a free cysteine at position 17 and two intramolecular disulfide bonds [4] . When rh-GCSF is produced by E. coli, the formation of disulfide bonds is either incorrect or inhibited because the reducing environment of bacterial cytosol, and it is accumulated in the form of IBs.
Earlier reports indicate that the levels of rh-GCSF expressed in E. coli was at moderate to high levels (10-35%) [7, 8] , and the yield of the final product was very poor and far from acceptable. This is probably because of unproductive downstream process technologies like isolation of protein IBs with low purity and recovery, misfolding, aggregate formation and unoptimized conditions of protein refolding, and chromatographic processes [5] . Therefore in this research has been tried to develop a well-organized and scalable process for recombinant human G-CSF from E. coli batch cultivation.
II. MATERIALS AND METHODS

A. Microorganism and vector system
E. coli BL21 (DE3) (Novagen, Inc.) was used as the host for rh-GCSF expression. This strain was transformed with a commonly available plasmid, pET23a inducible expression vector (Novagen,Inc.), in which the rh-GCSF gene (Biotehnology Research Center, Tehran, Iran) was inserted into the NotI and NdeI sites. Host cells were transformed with the plasmid using the calcium chloride procedure. Transformed cells were spread on several LB agar plates containing 100 mg/l ampicilin.
B. Media and solutions
LB (Luria-Bertani) medium was used for plate cultivation of E. coli strain BL21 (DE3) and M9 medium was used for preparation of seed culture. M9 medium was used for preparation of seed culture. The M9 modified medium consisted of 10 g glucose, 15 g K 2 HPO 4 , 7.5g KH 2 PO 4 , 2 g Citric acid, 2.5 g (NH 4 )2SO 4 
C. Batch Cultivation
Batch culture was started by adding 100 ml of an overnight-incubated seed culture (OD 600 = 0.7-1) into the bioreactor containing 900 ml of medium. The pH was controlled at 7±0.05 by the addition of 25% (w/v) NH 4 OH or 3 M H 3 PO 4 . Dissolved oxygen was controlled at 30-40% of air saturation by controlling both the inlet air and agitation rate. Foaming was controlled by adding silicon-antifoaming reagent. In batch culture, cells were induced by the addition of IPTG (1mmol/l) when initial DCW (2.2 g DCW/l) reached a considered level [6] . Then, the production phase continued until the growth ceased. All batch fermentations were performed twice.
D. Rh-GCSF purification
Cell lysis and IB recovery: The fermented broth was centrifuged at 4°C and 8000 g for 30 min and the obtained pellet was washed twice with 50 mM phosphate buffer pH 7.4.
The wet cells (50 g) were suspended in 200 ml of lysis buffer. The lysis buffer composition was 50 mM Tris-HCl containing 1 mM EDTA, 1 mM PMSF. The cells were broken by passing the medium through a homogenizer three times (NIRO-SOAVI) at 800 bar. The cells were cooled to 4°C between each pass. The cell homogenate was centrifuged for 30 min at 6000g at 4°C, the supernatant was discarded and the inclusion bodies recovered.
IBs washing: The IBs pellet obtained in previous step was resuspended in wash buffer and incubated 40 min and recovered by centrifugation at 25-28°C for 30 min at 8000 g . The washing protocol is 2.5 g l-1 Triton X-100 in 50 mM Tris-HCl pH 8.0 containing 5mM EDTA and 1 mM PMSF. In the second washing, the IBs pellet was resuspended in wash buffer and incubated 40 min and recovered by centrifugation at 25-28°C for 30 min at 8000 g. The washing protocol is 1 M urea.
IB solubilization and refolding: Washed inclusion bodies were dissolved in 30m M Tris-HCl, pH= 8, containing 6 M urea,1 mM EDTA and 100 mM GSH, The solution was incubated at 25-28 °C for 45 min and spun down at 10,000 g for 30 min to get rid of insoluble cell debris and recovered by centrifugation at 25-28 °C for 30 min at 8000 g. and then solubilized inclusion bodies was refolded by refolding buffer that the refolding buffer protocol is 30 mM Tris-HCl (pH =7.5), 2 mM GSSG, 20 mM GSH, 1 mM EDTA, 3M Urea and incubated 12 hours at 4°C. After completion of refolding, the protein pH was adjusted with 2 M citric acid and centrifuged at 10,000 g for 20 min at 4°C.
Anion Exchange Chromatography: The pH of Refolded protein was adjusted to 5-6 by adding 2 M Acetic acid and then loaded in mono Q column in FPLC (SYKAM-S2100). The column temperature and flow rate were maintained at 20 °C and 1 ml/min respectively throughout the process. The column was equilibrated with 3 bed vol. of 25 mM sodium acetate buffer (pH= 4.5). The refolded protein sample was directly loaded on to the column at the same flow rate. The column was extensively washed with 3 beds vol. of the same buffer but with 1 M NaCl.
E. SDS-PAGE
In the reduced SDS-PAGE 15% gel and three standards of rh-GCSF (Neupogen®, Roche, Germany), (PDgrastim, Pooyesh Darou, Iran) and a molecular weight marker (#SM0431, Fermentas) were used. Sample buffer [0.5 M Tris pH 6.8, 50% (v/v) glycerol, 100 g l-1 SDS, 20 g l-1 bromophenol blue and 50 g l-1 2-mercapto ethanol (2-ME) was added to three samples and standards before boiling for 5 min. The samples were loaded on to the gel and ran at a constant voltage of 120 V for 100 min. Gels were stained with Coomassie brilliant blue R250 [10].
F. Western blotting
For confirmation of rh-GCSF band in gel, western blotting with polyclonal human GCSF antibody was performed. Separated proteins on the SDS-PAGE gels were transferred into a poly-vinylidene fluoride (PVDF) membrane (Roche Diagnostic, Germany) for recognizing the exact existence of rh-GCSF. PVDF sheet was blocked with 3% BSA in TBS-T solution (20 mM Tris-HCl, pH 7.5, 150 mm NaCl, and 0.05% Tween 20). Then, anti-GCSF polyclonal antibody was added at a dilution of 1:500 in TBS-T solution for 1 h. A second incubation with HRP anti-rabbit (1:1000) in TBS-T was carried out and the third incubation of 5-10 min was done with Diaminobenzine (DAB) solution. (0.5 mg/ml DAB, 0.1% H2O2) [11] .
III. RESULTS AND DISCUSSION
A. Purification of human G-CSF • Cell lysis and IB isolation
The rh-GCSF IBs in the cytoplasm of E. coli were isolated by lysing the bacterial cells. The efficiency of cell lysis was experiential at different sonication pulses of 5, 10, 15 and 20 s and at a different homogenizer pressure (600, 800. 1200 bar) and at different times.
The highest IB recovery was observed by passing the medium through a homogenizer three times at 800 bar, and it is better to use homogenizer in industrial process. Cell lysis was measured by plating the lysate suspension on LB-agar followed by colony counting.
IB recovery was measured by the Bradford method. This condition was chosen as the optimum for further work. Thus optimization of the early stages of the downstream process will have an impact on the overall process yield and final product purity.
• IB washing
The IBs separated after homogenizer was found to be contaminated with endotoxins, host DNA and HCPs. These Impurities interfere with refolding and significantly affect the process yield and purity. Two-step wash procedure eliminates endotoxins, proteins and DNA of the host cell. Removal of these impurities and obtaining the IBs with high recovery and purity was demanding.
Therefore optimization of detergent concentration has effect on the efficiency of IB recovery.
We use different concentration of different detergents; finally we found that Triton X-100 was used to solubilize the bacterial cell wall components that infect the inclusion body preparation. Also, sodium deoxycholate to remove any residual cell debris particles, especially lipopolysaccharides units that contribute to the unacceptable levels of endotoxins in protein preparations from E. coli and urea are better than others.
• IB solubilization and refolding
Key to the development of an efficient and cost-effective denaturant-based solubilization step is the determination of the minimum amount of denaturant needed to solubilize the protein and to allow for full bioactivity recovery in the refolding step.
Because a method has been described for G-CSF extraction from IBs produced in E. coli used high amount of detergent and chaotropic agent, and hence additional steps had to be in use to eliminate these agents, so we optimize the amount of denaturant use in solubilization.
Since rh-GCSF is hydrophobic in nature and conductivity sensitive, the combination of denaturant/reducing agent has an impact on solubilization and refolding. Hence we use different concentration of urea (3, 6, 8 M) in different pH (6, 8, 12) (Fig1) .
The key to refolding is to remove enough denaturant to allow the protein to fold properly, but keep enough denaturant in the refolding buffer to allow proteins to fold/refold several times until attains the proper conformation protein.
• Anion Exchange Chromatography
The ion-exchange column is primarily useful for the removal of endotoxins, nucleic acids, HCPs and product-related impurities.
In this study we use FPLC (SYKAM-S2100) with mono Q Column. The results obtained determine improvement of the method for effective removal of impurities and high recovery of protein with a monomer peak purity of>98 %. In the present study we envisage a simple, fast, reliable and reproducible process for higher yields and a quality product with high purity.
The SDS-PAGE gel electrophoresis shows that the purity of the purified rh-GCSF by IEC is over than 99%. The final step of the purification showed a single band of 18.8 kDa, similar to reference standard. The same general pattern was revealed when the sample shown in Figure 3 was transferred from SDS-PAGE to a nitrocellulose membrane and immunodetected with G-CSF specific antiserum, confirming a typical profile (Fig2, Fig.3 ).
IV. CONCLUSION
In the present study, we developed an efficient and scalable procedure for production and purification of recombinant human (rh-GCSF) of E. coli. By the using of the new developed method, 2.2 g l -1 rh-GCSF was produced in batch cultivation with recovery yield about 40% and with purity over than 99%. The process established in this study may be functional in the recovery of other proteins expressed in E. coli as cytoplasmic IBs. 
